Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8247312 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 6 Pages |
Abstract
Conclusion: Combined-modality therapy, based on high-dose methotrexate, results in improved survival outcomes in PCNSL. The risk of neurotoxicity for patients aged >60 years is unacceptable with this regimen, although survival outcomes for patients aged >60 years were higher than in many other series.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Peter C. (F.R.A.N.Z.C.R.), Daniel E. (F.R.A.N.Z.C.R.), Gary (F.R.A.N.Z.C.R.), K.-H. (F.R.A.N.Z.C.R.), Michael B. (F.R.A.N.Z.C.R.), Michael G. (F.R.A.N.Z.C.R.), Ian N. (F.R.A.C.P.), Grant E. (F.R.A.N.Z.C.R.),